THERAPEUTIC OUTCOMES ON IL-17 LEVELS WITH CD20 VERSUS TNF-Α INHIBITORS IN RHEUMATOID ARTHRITIS

Authors: Nabeel Al-Hashimi Hussein

DOI: 10.5281/zenodo.17463431

Published: October 2025

PDF XML Read Online

Abstract

<p><strong><em>Back ground: </em></strong><em>Rheumatoid&nbsp;&nbsp;&nbsp;&nbsp; arthritis&nbsp;&nbsp;&nbsp; (RA)&nbsp;&nbsp;&nbsp; is&nbsp;&nbsp;&nbsp; a&nbsp; chronic&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp; systemic&nbsp;&nbsp; , inflammatory&nbsp; disorder that may affect many tissues and organs ,once a diagnosis is made , the main treatment goals are to control&nbsp; disease activity and slow&nbsp; the rate of joint damage&nbsp; ,in addition to minimizing pain, stiffness, inflammation and complications. Important&nbsp;&nbsp;&nbsp; role of IL-17 in the development&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp; disease&nbsp;&nbsp; and&nbsp;&nbsp; can be used as a marker for monitoring of disease activity.&nbsp; </em></p> <p><strong><em>&nbsp;Aim of the Study </em></strong><em>The&nbsp;&nbsp; aim of&nbsp;&nbsp; the present study to evaluate the effects of CD20 inhibitors&nbsp;&nbsp;&nbsp; therapy&nbsp;&nbsp;&nbsp; in comparison to effects of TNF α inhibitors therapy&nbsp;&nbsp;&nbsp; on&nbsp;&nbsp; IL-17&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp; patients&nbsp;&nbsp; with active rheumatoid arthritis.</em></p> <p><strong><em>Results:-</em></strong><em> results obtained in the present study showed that serum level of IL-17were also&nbsp; decrease significantly in&nbsp;&nbsp; patients&nbsp;&nbsp; treated&nbsp; with&nbsp; Rituximab&nbsp; group 3 ( 2.28 )&nbsp; than those&nbsp;&nbsp; of&nbsp; group 2 Etanercept&nbsp; (anti-TNFα) treate d&nbsp; group&nbsp;&nbsp;&nbsp; patients (3.3).&nbsp; </em></p> <p><strong><em>Conclusion: - </em></strong><em>the&nbsp;&nbsp; role of IL-17 in the development&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp; disease&nbsp;&nbsp; and&nbsp;&nbsp; can be used as a marker for monitoring <strong>of</strong> disease activity</em></p>

Full Text

No full text available

Cite this Article

DOI: 10.5281/zenodo.17463431

References

  1. No references available.